Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Neurelis, Inc.

## Sitemaps

- [XML Sitemap](https://www.neurelis.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [NEURELIS CEO CRAIG CHAMBLISS NAMED EY US ENTREPRENEUR OF THE YEAR® 2026 PACIFIC SOUTHWEST AWARD WINNER](https://www.neurelis.com/neurelis-ceo-craig-chambliss-named-ey-us-entrepreneur-of-the-year-2026-pacific-southwest-award-winner/) - Recognition honors business leaders for their ingenuity, courage, and entrepreneurial spirit San Diego, CA – June 15, 2026 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced its Founder and Chief Executive Officer Craig Chambliss was named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2026 Pacific Southwest
- [NEURELIS HELPS SUPPORT NATIONAL NETWORK OF EPILEPSY AWARENESS AND SUPPORT AT FIRST EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT WALT DISNEY WORLD](https://www.neurelis.com/neurelis-helps-support-national-network-of-epilepsy-awareness-and-support-at-first-epilepsy-awareness-day-and-education-expo-at-walt-disney-world/) - Company’s Ambassadors to share their journeys with epilepsy and meaningfully connect with the epilepsy community in first east coast event San Diego, CA – April 23, 2026 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will join the epilepsy community at Epilepsy Awareness Day at Walt Disney World, one
- [NEURELIS TO PRESENT ANALYSES OF IMMEDIATE-USE SEIZURE TREATMENT AT THE AMERICAN ACADEMY OF NEUROLOGY ANNUAL MEETING](https://www.neurelis.com/neurelis-to-present-analyses-of-immediate-use-seizure-treatment-at-the-american-academy-of-neurology-annual-meeting/) - Presentations to highlight analyses of both seizure termination and healthcare resource utilization as they relate to use of diazepam nasal spray San Diego, CA – April 16, 2026 – Neurelis, Inc., today announced details of two poster presentations at the American Academy of Neurology (AAN) Annual Meeting to be held April 18-22 in person
- [NEURELIS PROVIDES BUSINESS UPDATE HIGHLIGHTING TRANSFORMATIONAL 2025 RESULTS](https://www.neurelis.com/neurelis-provides-business-update-highlighting-transformational-2025-results/) - 2025 Net Revenue of $295-300M, EBITDA margin of 30%+ Expansion of VALTOCO (diazepam nasal spray) Patent Portfolio, Extending Market Exclusivity with multiple issuances through 2032 Accelerated Uptake with VALTOCO FDA Label Expansion Approval Including 2 to 5 years of Age San Diego, CA – January 12, 2026 – Neurelis, Inc., the innovator behind VALTOCO®
- [NEURELIS TO PRESENT CLINICAL DATA AT AMERICAN EPILEPSY SOCIETY ANNUAL MEETING](https://www.neurelis.com/neurelis-to-present-clinical-data-at-american-epilepsy-society-annual-meeting/) - Collection of eight posters include analyses of data from studies of diazepam nasal spray in treatment of episodes of frequent seizures in people with epilepsy aged 2-65 years San Diego, CA – December 5, 2025 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will participate in the American Epilepsy Society
- [NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT](https://www.neurelis.com/neurelis-to-participate-in-sofies-journey-epilepsy-awareness-day-and-education-expo-at-disneyland-resort/) - Company will be joined by its Ambassadors to engage epilepsy community and share their journeys San Diego, CA – November 10, 2025 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will join the epilepsy community at the 13th Annual Sofie’s Journey Epilepsy Awareness Day & Education Expo at Disneyland (EADDL),
- [NEURELIS TO PRESENT STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT SYMPTOMATIC CEREBRAL CAVERNOUS MALFORMATIONS (CCM), AT ANNUAL CCM MEETING](https://www.neurelis.com/neurelis-to-present-study-of-nrl-1049-a-rho-kinase-rock-inhibitor-with-potential-to-treat-symptomatic-cerebral-cavernous-malformations-ccm-at-annual-ccm-meeting/) - Phase 1 clinical study data on NRL-1049 shows dose-proportional increase in exposure and favorable safety profile San Diego, CA – November 6, 2025 – Neurelis, Inc., today announced it will present at the Alliance to Cure Cavernous Malformation (CCM) 21st International CCM Scientific & Clinical Meeting to be held November 6-7, 2025, in Atlanta, Georgia.
- [NEURELIS TO HIGHLIGHT DATA FROM A STUDY OF DIAZEPAM NASAL SPRAY IN PEDIATRIC PATIENTS AT THE CHILD NEUROLOGY SOCIETY ANNUAL MEETING](https://www.neurelis.com/neurelis-to-highlight-data-from-a-study-of-diazepam-nasal-spray-in-pediatric-patients-at-the-child-neurology-society-annual-meeting/) - Poster presentations provide insights into timing of dosing and seizure termination, as well as interval between episodes of frequent seizures following treatment with diazepam nasal spray San Diego, CA – October 8, 2025 – Neurelis, Inc., the innovator behind VALTOCO® (diazepam nasal spray), today announced it will present two posters at the 54th Child Neurology Society
- [NEURELIS ANNOUNCES FDA APPROVAL FOR IMMEDIATE USE SEIZURE MEDICATION VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5](https://www.neurelis.com/neurelis-announces-fda-approval-for-immediate-use-seizure-medication-valtoco-diazepam-nasal-spray-in-ages-2-to-5/) - VALTOCO maintains orphan drug exclusivity for VALTOCO to treat episodes of frequent seizures San Diego, CA – [April, 16, 2025] – Neurelis, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved VALTOCO® (diazepam nasal spray) for short-term treatment of seizure clusters (also known as “acute repetitive seizures”) that are different from
- [Neurelis Initiates Pivotal Clinical Program for NRL-1 in the Treatment of Acute Repetitive Seizures](https://www.neurelis.com/neurelis-news-pivotal-clinical-program/) - Following the receipt of Orphan Drug Designation for their lead product, NRL-1 (intranasal diazepam), Neurelis, Inc. ("Neurelis") today announced the receipt of guidance from the FDA for the final clinical trial requirements necessary for approval of NRL-1. NRL-1 is being developed for pediatric, adolescent, and adult epilepsy patients who experience Acute Repetitive Seizures. Neurelis has
- [Neurelis Receives FDA Orphan Drug Designation for NRL-1 in the Treatment of Acute Repetitive Seizures](https://www.neurelis.com/neurelis-news-fda-orphan-drug-designation/) - Neurelis, Inc. ("Neurelis") today announced receipt of Orphan Drug Designation from the FDA for their lead program, NRL-1 (intranasal diazepam) for pediatric, adolescent, and adult epilepsy patients who experience acute repetitive seizures. The FDA's Orphan Drug Designation program provides orphan status to drugs intended for the safe and effective treatment of rare disorders that affect
- [Neurelis Finalizes Series A Financing to Advance Lead Program to NDA Filing](https://www.neurelis.com/neurelis-news-finalizes-series-financing/) - Neurelis, Inc., a specialty pharmaceutical company focused on the treatment of central nervous system disorders, today announced that it has finalized a Series A financing round. The investment, led by LYZZ Capital, is intended to advance the company's lead program, NRL-1 (intranasal diazepam), through the remaining clinical work in preparation for FDA submission of a
- [Neurelis Recieves FDA Fast Track Designation for NRL-1](https://www.neurelis.com/neurelis-news-fda-fast-track/) - Neurelis, Inc. today announced that the US Food and Drug Administration (FDA) has designated NRL-1 (intranasal diazepam) as a Fast Track Development program for the management of selected, refractory patients with epilepsy, on a stable regimen of anti-epileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizures – also referred to
- [Neurelis Completes Series B Financing](https://www.neurelis.com/neurelis-news-completes-series-b-financing/) - Neurelis, Inc. today announced that it has finalized a Series B financing round led by HBM Healthcare Investments. In addition, LYZZ Capital, which led the Series A funding for Neurelis, has participated in the Series B round. The company will utilize the funds to complete clinical trials for NRL-1 (intranasal diazepam), prepare the planned New Drug
- [Neurelis Expands Worldwide Patent Portfolio with Latest Issuance in Japan](https://www.neurelis.com/neurelis-news-expands-worldwide-patent-portfolio/) - Neurelis, Inc. today announced that the Japan Patent Office (JPO) recently allowed JP Application No. 2014-515967 related to Neurelis' NRL-1 intranasal diazepam formulation. The patent, when issued, will be in force at least until 2032. NRL-1's formulation incorporates the unique combination of a Vitamin E-based solvent and Intravail® absorption enhancement with the goal of obtaining unparalleled absorption,
- [Neurelis Files New Drug Application With The FDA For VALTOCO™ (Diazepam Nasal Spray), An Investigational Treatment For Pediatric, Adolescent And Adult Epilepsy Patients](https://www.neurelis.com/neurelis-news-neurelis-files-new-drug-application-fda-valtocotm-nasal-spray-investigational-treatment-pediatric/) - SAN DIEGO, CA – Sept. 25, 2018 -- Neurelis, Inc. today announced that the company has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for VALTOCOTM (diazepam nasal spray) as a treatment for epilepsy patients six years and older who experience increased bouts of seizure activity, also known as
- [Neurelis Announces Acquisition Of Aegis Therapeutics, A  Leading Drug Delivery Technology Company](https://www.neurelis.com/neurelis-news-neurelis-acquires-aegis-therapeutics-press-release/) - Aegis’ Intravail® drug delivery technology utilized in Neurelis’ VALTOCO™ Nasal Spray, a novel investigational treatment for epilepsy patients SAN DIEGO, CA – December 3, 2018 -- Neurelis, Inc. today announced the acquisition of Aegis Therapeutics, a San Diego-based drug delivery technology company. Aegis Therapeutics’ proprietary portfolio includes Intravail®, ProTek® and Hydrogel™, three non-invasive drug delivery
- [NEURELIS ANNOUNCES COMPLETION OF SENIOR MANAGEMENT TEAM BUILDOUT TO SUPPORT THE ANTICIPATED COMMERCIAL LAUNCH OF VALTOCO™](https://www.neurelis.com/neurelis-news-neurelis-announces-completion-senior-management-team-buildout-support-anticipated-commercial-launch/) - -- Neurelis’ lead product candidate for seizures, VALTOCO™ (diazepam nasal spray), currently under FDA review -- Company’s team members are all seasoned pharmaceutical industry executives with vast experience in CNS and epilepsy SAN DIEGO, CA – April 22, 2019 – Neurelis, Inc., a privately held specialty pharmaceutical company focused on licensing, developing, and commercializing product candidates
- [INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS, SECURES $20M FINANCING FROM DEERFIELD MANAGEMENT](https://www.neurelis.com/intravailr-licensee-ars-pharmaceuticals-secures-20m-financing-deerfield-management/)
- [Neurelis Announces First Product Approved Using The Company’s  Intravail® Platform](https://www.neurelis.com/neurelis-news-neurelis-announces-first-product-approved-using-intravail-press-release/) - -- Dr. Reddy’s Laboratories and its U.S. subsidiary, Promius Pharma, announced U.S. FDA approval on January 28 for its migraine treatment TOSYMRA™ (sumatriptan nasal spray 10 mg) in the United States -- This is the first FDA approval of an investigational drug utilizing the science of Intravail® -- Neurelis’ lead product candidate for seizures, VALTOCO™,
- [Neurelis Announces That Intravail® Licensee ARS Pharmaceuticals Intranasal Epinephrine Program Given Fast Track Designation](https://www.neurelis.com/neurelis-news-neurelis-announces-intravail-licensee-ars-pharmaceuticals-intranasal-epineprhine-program-given/) - -- ARS Pharmaceuticals announced that ARS-1, an intranasal epinephrine spray in development to treat severe allergic reactions, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) SAN DIEGO, CA – February 20, 2019 – Neurelis, Inc. announced today that its Intravail® licensing partner, ARS Pharmaceuticals, Inc., received Fast Track designation from
- [Neurelis Announces Two Poster Presentations At The Annual Meeting Of The American Academy Of Neurology](https://www.neurelis.com/neurelis-news-neurelis-announces-two-poster-presentations-annual-meeting-american-academy-neurology/) - -- Neurelis’ lead product candidate for seizures, VALTOCO™ (diazepam nasal spray), currently under FDA review SAN DIEGO, CA – April 29, 2019 -- Neurelis, Inc., a privately held specialty pharmaceutical company focused on licensing, developing, and commercializing product candidates for epilepsy and the broader central nervous system (CNS) market, announced today that the company will
- [UPSHER-SMITH LABORATORIES ANNOUNCES THE LAUNCH OF TOSYMRA™ USING NEURELIS’ INTRAVAIL® TECHNOLOGY](https://www.neurelis.com/upsher-smith-laboratories-announces-launch-tosymratm-using-neurelis-intravailr-technology/)
- [NEURELIS ANNOUNCES THREE POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE CHILD NEUROLOGY SOCIETY](https://www.neurelis.com/neurelis-announces-three-poster-presentations-annual-meeting-child-neurology-society/) - — Neurelis’ investigational product candidate, VALTOCO® (diazepam nasal spray), currently under review by the U.S. Food and Drug Administration SAN DIEGO, CA – October 22, 2019 – Neurelis, Inc., a privately held specialty pharmaceutical company focused on licensing, developing and commercializing product candidates for epilepsy and the broader central nervous system (CNS) market, announced today
- [NEURELIS ANNOUNCES NINE POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY](https://www.neurelis.com/neurelis-announces-nine-poster-presentations-annual-meeting-american-epilepsy-society/) - — Neurelis’ investigational product candidate, VALTOCO® (diazepam nasal spray), currently under review by the U.S. Food and Drug Administration SAN DIEGO, CA – December 5, 2019 – Neurelis, Inc., a privately held specialty pharmaceutical company focused on licensing, developing and commercializing product candidates for epilepsy and the broader central nervous system market, announced today that
- [NEURELIS ANNOUNCES RAPID AND BROAD PAYER COVERAGE OF THE COMPANY'S FLAGSHIP PRODUCT, VALTOCO® (DIAZEPAM NASAL SPRAY)](https://www.neurelis.com/neurelis-news-neurelis-announces-rapid-and-broad-payer-coverage/) - — More than 176 million lives in the U.S. now covered by payers/managed care/insurance plans within months of FDA approval of VALTOCO, the first and only nasal spray treatment of seizure clusters in patients 6 years of age and older — Neurelis' patient assistance program supports eligible patients who have no health insurance — Co-pay
- [NEURELIS ANNOUNCES FDA APPROVAL FOR SEIZURE RESCUE TREATMENT VALTOCO® (DIAZEPAM NASAL SPRAY) THAT INCORPORATES THE SCIENCE OF INTRAVAIL® FOR CONSISTENT AND RELIABLE ABSORPTION](https://www.neurelis.com/neurelis-news-neurelis-announces-fda-approval-seizure-rescue-treatment-valtocor-diazepam-nasal-spray-incorporates/) - — VALTOCO (diazepam nasal spray) is approved by the U.S. Food and Drug Administration (FDA) for use by a care partner outside of the medical setting for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern — VALTOCO
- [NEURELIS TO PRESENT AT SVB LEERINK 9th ANNUAL GLOBAL HEALTHCARE CONFERENCE](https://www.neurelis.com/neurelis-news-neurelis-present-svb-leerink-9th-annual-global-healthcare-conference/) - SAN DIEGO, CA – February 24, 2020 – Neurelis, Inc., today announced that the company will be participating in the SVB Leerink 9th Annual Global Healthcare Conference at Lotte New York Palace, New York City. Neurelis President and CEO Craig Chambliss will present at 2:15 pm EST on Tuesday, February 25. About Neurelis Neurelis, Inc.
- [NEURELIS ANNOUNCES COMMERCIAL AVAILABILITY OF VALTOCO® (DIAZEPAM NASAL SPRAY) FOR SEIZURE CLUSTER RESCUE](https://www.neurelis.com/neurelis-news-neurelis-announces-commercial-availability-valtocor-diazepam-nasal-spray-seizure-cluster-rescue/) - — VALTOCO is the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older — Copay and patient assistance program to be provided by Neurelis for eligible VALTOCO patients SAN DIEGO, CA – March 2, 2020 – Neurelis, Inc., announced today the commercial availability
- [NEURELIS ANNOUNCES THAT INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS’ INTRANASAL EPINEPHRINE PRODUCT, DEMONSTRATES BIOEQUIVALENT EXPOSURE TO EPINEPHRINE INJECTORS](https://www.neurelis.com/neurelis-news-neurelis-announces-intravailr-licensee-ars-pharmaceuticals-intranasal-epinephrine-product/) - — ARS Pharmaceuticals’ lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has previously been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) — Neurelis’ lead product, VALTOCO® (diazepam nasal spray), approved by the FDA for seizure cluster rescue, also utilizes Intravail® as a key component of its formulation
- [NEURELIS ANNOUNCES TOTAL OF NINE POSTER PRESENTATIONS FOR THE AANN, AMCP, AND AAN ANNUAL MEETINGS](https://www.neurelis.com/neurelis-news-neurelis-announces-total-nine-poster-presentations-aann-amcp-and-aan-annual-meetings/) - — Data supports pharmacokinetic and safety profile for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults — Data also further highlights the permeation enhancer potency of Intravail® for both small and large molecules;
- [Neurelis Announces Program to Investigate the Safety and Pharmacokinetics of VALTOCO® (diazepam nasal spray) in Children Aged 2 to 5](https://www.neurelis.com/neurelis-news-neurelis-announces-program-to-investigate/) - SAN DIEGO, CA – September 23, 2020 – Neurelis, Inc., announced today that it will be investigating the safety and pharmacokinetics of the company's lead product, VALTOCO® (diazepam nasal spray), in children with epilepsy aged two to five. VALTOCO is currently available for adults and pediatric patients 6 years of age and older. This is
- [Neurelis Announces Four Poster Presentations for the Joint Meeting of the International Child Neurology Association and Child Neurology Society](https://www.neurelis.com/neurelis-news-neurelis-four-poster-presentations-joint-meeting-icna-cns/) - — Data continue to support the unique clinical attributes for Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in pediatric patients 6 years of age and older, adolescents, and adults — Data also highlight that 88 percent of treated seizure episodes used a single dose
- [Neurelis Announces FDA Approval of Extended Expiration Dating for VALTOCO® (diazepam nasal spray)](https://www.neurelis.com/neurelis-news-fda-approval-extended-expiration-dating/) - SAN DIEGO, CA – October 19, 2020 – Neurelis, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted extended expiration dating for the company's lead product, VALTOCO® (diazepam nasal spray). VALTOCO was approved by the FDA on January 10, 2020, for the acute treatment of intermittent, stereotypic episodes of frequent seizure
- [Neurelis Announces National Wholesale and Retailer Chains and Independent Pharmacies Are Now Stocking VALTOCO® (diazepam nasal spray)](https://www.neurelis.com/neurelis-news-neurelis-announces-national-wholesale/) - SAN DIEGO, CA – November 9, 2020 – Neurelis, Inc., announced today that the company's lead product, VALTOCO® (diazepam nasal spray), is now available through pharmacies nationwide. VALTOCO was approved by the FDA earlier this year for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that
- [Neurelis Completes Pre-IND Meeting With FDA to Establish Clinical Development Program for NRL-4 in the Treatment of Acute Agitation Associated With Schizophrenia and Bipolar 1 Mania in Adults](https://www.neurelis.com/neurelis-news-neurelis-completes-pre-ind-meeting/) - SAN DIEGO, CA – November 23, 2020 – Neurelis, Inc., announced today that it has concluded a pre-Investigational New Drug (IND) Application meeting with the U.S. Food and Drug Administration (FDA) regarding NRL-4. The FDA provided direction for the clinical development pathway for the investigational treatment. NRL-4 is being investigated as a noninvasive, easy-to-administer rescue
- [Neurelis Announces 12 Poster Presentations for the Annual Meeting of the American Epilepsy Society](https://www.neurelis.com/neurelis-news-neurelis-announces-12-poster-presentations-american-epilepsy-society/) - — Abstracts continue to demonstrate the safety and unique clinical attributes of Neurelis' lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for episodes of frequent seizure activity in pediatric patients 6 years of age and older, adolescents, and adults — Data also highlight the ability for patients to self-administer VALTOCO
- [NEURELIS ANNOUNCES ACQUISITION OF RIGHTS TO PORTFOLIO OF NEW CHEMICAL ENTITY (NCE) COMPOUNDS TARGETING CEREBRAL CAVERNOUS MALFORMATIONS, A RARE CNS DISORDER](https://www.neurelis.com/neurelis-announces-acquisition-rights-portfolio-new-chemical-entity-nce-compounds-targeting/) - Adds to Neurelis’s growing pipeline of innovative neuroscience programs There are no currently FDA-approved treatments for Cerebral Cavernous Malformations (CCMs) Neurelis intends to submit an Investigational New Drug (IND) application with the FDA on BioAxone’s lead compound, BA-1049, in 2022 SAN DIEGO, CA — June 21, 2021 — Neurelis, Inc., announced today that it has
- [NEURELIS ANNOUNCES CLOSE OF $114 MILLION SERIES D FINANCING ROUND TO ADVANCE NEUROSCIENCE FOCUS](https://www.neurelis.com/neurelis-announces-close-114-million-series-d-financing-round-advance-neuroscience-focus/) - 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company Funds will enhance growth and commercial penetration of company’s lead orphan drug product, VALTOCO® (diazepam nasal spray), and support pipeline development and expansion Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors SAN DIEGO,
- [NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS FOR THE ANNUAL MEETING OF THE ACADEMY OF MANAGED CARE PHARMACY](https://www.neurelis.com/neurelis-announces-two-poster-presentations-annual-meeting-academy-managed-care-pharmacy/) - Clinical studies support effectiveness and safety profile for Neurelis’ lead product, VALTOCO®(diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older Data presented at AMCP shows that just a single dose of VALTOCO was needed in 87.4% of seizure clusters
- [NEURELIS ANNOUNCES FIVE POSTER PRESENTATIONS FOR THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY](https://www.neurelis.com/neurelis-announces-five-poster-presentations-annual-meeting-american-academy-neurology/) - Data from clinical studies continue to support effectiveness, tolerability and safety profile for Neurelis’ lead product, VALTOCO® (diazepam nasal spray), the first and only nasal spray treatment for seizure cluster rescue in adult and pediatric patients 6 years of age and older Survey data presented at AAN shows that nearly 80% of patients were comfortable
- [NEURELIS SECURES SENIOR TERM LOAN FACILITY OF UP TO $150 MILLION FROM ORBIMED](https://www.neurelis.com/neurelis-secures-senior-term-loan-facility-150-million-orbimed/) - Financing to fund commercialization of Neurelis’ lead product, VALTOCO® (diazepam nasal spray), and to advance its product pipeline while allowing the company to explore certain additional strategic opportunities SAN DIEGO, CA — August 11, 2021 — Neurelis, Inc., announced today that it has completed a senior term loan facility of up to $150 million from
- [NEURELIS INITIATES STUDY OF VALTOCO® (diazepam nasal spray) IN CHILDREN WITH SEIZURE CLUSTERS AGED TWO TO FIVE](https://www.neurelis.com/neurelis-initiates-study-valtocor-diazepam-nasal-spray-children-seizure-clusters-aged-two-five/) - VALTOCO is currently approved by the FDA as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters or acute repetitive seizures) that are distinct from an individual’s usual seizure pattern in patients with epilepsy 6 years of age and older SAN DIEGO, CA — September 20, 2021 — Neurelis, Inc.
- [NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE CHILD NEUROLOGY SOCIETY](https://www.neurelis.com/neurelis-announces-two-poster-presentations-annual-meeting-child-neurology-society/) - Subgroup analyses from the long-term safety study of VALTOCO® (diazepam nasal spray) produced favorable safety and tolerability results in children (6-11 years of age) and adolescents (12-17 years of age) who experience seizure clusters A post-hoc analysis also showed that 89% of children and adolescents with epilepsy used one dose of VALTOCO (within a 24-hour
- [NEURELIS ANNOUNCES ADDITION OF BRITTANY BRADRICK AS CFO AND EXPANSION OF LEADERSHIP TEAM AND BOARD OF DIRECTORS](https://www.neurelis.com/neurelis-announces-addition-brittany-bradrick-cfo-and-expansion-leadership-team-and-board-directors/) - Corporate finance veteran David Smith named to company’s Board of Directors SAN DIEGO, CA — October 18, 2021 — Neurelis, Inc., announced today that it has made the following additions to its leadership team: • Brittany Bradrick has been named Chief Financial Officer at Neurelis • David Smith has been added to the company’s Board
- [NEURELIS ANNOUNCES 16 POSTER PRESENTATIONS AT THE ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY](https://www.neurelis.com/neurelis-announces-16-poster-presentations-annual-meeting-american-epilepsy-society/) - ​​​​​​Subgroup analyses from the long-term safety study of VALTOCO® (diazepam nasal spray) demonstrated favorable safety and tolerability results in children (6-11 years of age), adolescents (12-17 years of age) and adults who experience seizure clusters Safety and effectiveness results for VALTOCO remained consistent in subgroups of patients, including subgroups of patients with concomitant clobazam use,
- [DATA FROM NOVEL, EXPLORATORY ANALYSIS OF INTERMITTENT VALTOCO® (DIAZEPAM NASAL SPRAY) CIV USE INDICATES MORE THAN TWO-FOLD INCREASE IN MEAN INTERVAL BETWEEN SEIZURE CLUSTERS](https://www.neurelis.com/data-novel-exploratory-analysis-intermittent-valtocor-diazepam-nasal-spray-civ-use-indicates-more/) - Neurelis presents two posters at the 2nd North American Epilepsy Congress (NAEC) highlighting new analysis of change in timing between seizure clusters across 12 months, and final effectiveness and safety data from the Phase 3, open-label, repeat-dose study of VALTOCO SAN DIEGO, CA — May 5, 2022— Neurelis, Inc., today announced findings from a novel,
- [NEURELIS ANNOUNCES PARTNERSHIP WITH RICK HARRISON, HOST OF TV’S “PAWN STARS” AND EPILEPSY ADVOCATE, TO RAISE AWARENESS OF EPILEPSY AND NEED FOR MORE EDUCATION REGARDING SEIZURE EMERGENCIES](https://www.neurelis.com/neurelis-announces-partnership-rick-harrison-host-tvs-pawn-stars-and-epilepsy-advocate-raise/) - SAN DIEGO, CA — December 3, 2021 — Neurelis, Inc., announced today that it is partnering with epilepsy education advocate Rick Harrison, star of TV’s “Pawn Stars,” to raise awareness of epilepsy and the need for more education regarding seizure emergencies. Harrison was diagnosed at age 8 with focal onset aware seizures and suffered from
- [NEURELIS SIGNS EXCLUSIVE LICENSING AGREEMENT WITH ACULYS PHARMA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN JAPAN AND THE ASIA-PACIFIC REGION](https://www.neurelis.com/neurelis-signs-exclusive-licensing-agreement-aculys-pharma-development-and-commercialization/) - SAN DIEGO, CA — January 25, 2022 — Neurelis, Inc. announced that it has signed an exclusive licensing agreement with Aculys Pharma, Inc. for the development and commercialization of VALTOCO® (diazepam nasal spray) in Japan and the Asia-Pacific region which includes Australia, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, New Zealand, Philippines, South Korea, Thailand and
- [NEURELIS ANNOUNCES THREE POSTER PRESENTATIONS AT THE 2022 ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY](https://www.neurelis.com/neurelis-announces-three-poster-presentations-2022-annual-meeting-american-academy-neurology/) - Final results from long-term, open-label, repeat-dose Phase 3 study of VALTOCO® (diazepam nasal spray) for episodes of frequent seizure activity include findings on ease of dosing and quality of life Investigational analysis on timing of a second dose of VALTOCO® SAN DIEGO, CA — April 4, 2022 — Neurelis, Inc., will present three posters from the
- [NEURELIS EXPANDS INTELLECTUAL PROPERTY ESTATE FOR VALTOCO®, A PATIENT-CENTRIC NASAL SPRAY FOR ACUTE TREATMENT OF EPISODES OF FREQUENT SEIZURE ACTIVITY](https://www.neurelis.com/neurelis-expands-intellectual-property-estate-valtocor-patient-centric-nasal-spray-acute-treatment/) - Fifth patent combined with a growing body of clinical data demonstrate safety and effectiveness of VALTOCO in this patient population, enhancing potential to expand clinical and commercial value. SAN DIEGO, CA — April 26, 2022 — Neurelis, Inc., a neuroscience-based company dedicated to enhancing therapeutic benefits and addressing significant unmet needs in managing central nervous system
- [NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE](https://www.neurelis.com/neurelis-highlight-valtoco-diazepam-nasal-spray-civ-development-program-updates-16th-eilat/) - Company to provide an overview of studies and publications for VALTOCO® in treating episodes of frequent seizure activity (seizure clusters) SAN DIEGO, CA ̶ May 31, 2022— Neurelis, Inc., today announced it will provide highlights of its clinical development program for VALTOCO® (diazepam nasal spray), an acute therapy for episodes of frequent seizure activity (seizure
- [NEURELIS PRESENTED CLINICAL DATA SUPPORTING SEIZURE CLUSTER INTERVAL ANALYSIS AT THE EPILEPSY FOUNDATION PIPELINE CONFERENCE](https://www.neurelis.com/neurelis-presented-clinical-data-supporting-seizure-cluster-interval-analysis-epilepsy-foundation/) - Results of a post hoc analysis of Phase 3 clinical trial data may support a previously unrecognized effect of intermittent rescue therapy SAN DIEGO, CA - June 7, 2022 — Neurelis, Inc., announced findings from a novel, investigational analysis of VALTOCO® (diazepam nasal spray) CIV. The data indicate that patients using the therapy had a
- [NEURELIS STUDY PUBLISHED IN EPILEPSIA, A WORLD-CLASS JOURNAL DEDICATED TO EPILEPSY](https://www.neurelis.com/neurelis-study-published-epilepsia-world-class-journal-dedicated-epilepsy/) - SAN DIEGO, CA - June 9, 2022 — Neurelis, Inc., announced the publication of a study recently available online in the peer-reviewed, scientific journal Epilepsia. Epilepsia is the world's leading journal of original scientific research on multiple aspects of epilepsy. Epilepsia publishes reviews, opinion pieces, and guidelines that foster understanding and aim to improve the
- [NEURELIS, INC., NAMED TO LIST OF BEST PLACES TO WORK IN SoCAL 2022](https://www.neurelis.com/neurelis-inc-named-list-best-places-work-socal-2022/) - Company culture cultivates passioned innovation and purpose in employees to empower those impacted by epilepsy and other rare disorders SAN DIEGO, CA — August 18, 2022 — Neurelis, Inc., is pleased to announce it has been named one of the Best Places to Work in SoCal 2022 by Best Companies Group (BCG), a BridgeTower Media
- [Neurelis, Inc., Little Angels Service Dogs Present Aug. 25 “Barks ‘n Blues Music & More” Concert to Build Epilepsy Awareness at Local Community Event](https://www.neurelis.com/neurelis-inc-little-angels-service-dogs-present-aug-25-barks-n-blues-music-more-concert-build/) - SAN DIEGO, CA — August 19, 2022 — Neurelis and Little Angels Service Dogs are proud to present the “Barks ‘n Blues Music & More” concert for epilepsy awareness at the Quartyard, 1301 Market St., San Diego, Thursday, Aug. 25 at 5 p.m. PT. Featured performers include five-time San Diego Music Award winner, Whitney Shay,
- [STUDY PUBLISHED IN EPILEPSIA SHOWS SIGNIFICANT PROLONGATION OF TIME INTERVALS BETWEEN SEIZURE CLUSTERS TREATED WITH NEURELIS’ VALTOCO® (DIAZEPAM NASAL SPRAY) CIV](https://www.neurelis.com/study-published-epilepsia-shows-significant-prolongation-time-intervals-between-seizure-clusters/) - Novel clinical data highlights the potential for future research into additional benefits of rescue medications in treating individual seizure clusters SAN DIEGO, CA — September 7, 2022 — Neurelis, Inc., announced the recent online publication of a novel data analysis, evaluating the time interval between seizure clusters, or SEIzure interVAL (SEIVAL) in Epilepsia that indicates
- [NEURELIS TO SHARE CLINICAL STUDY DESIGN INSIGHTS FOR INVESTIGATION OF VALTOCO® (DIAZEPAM NASAL SPRAY) IN AGES 2 TO 5 AT CHILD NEUROLOGY SOCIETY ANNUAL MEETING](https://www.neurelis.com/neurelis-share-clinical-study-design-insights-investigation-valtocor-diazepam-nasal-spray-ages-2-5/) - Presentation highlights study-enrollment challenges and strategies to overcome potential barriers
- [NEURELIS STRENGTHENS LEADERSHIP TO FURTHER ENHANCE GROWING MOMENTUM IN SEIZURE-RESCUE MARKET](https://www.neurelis.com/neurelis-strengthens-leadership-further-enhance-growing-momentum-seizure-rescue-market/) - Company promotes Brittany Bradrick to Chief Operating Officer (COO) and Chief Financial Officer (CFO) SAN DIEGO, CA — October 6, 2022 — Building on a transformative year of growth and success, Neurelis, Inc., announced today that it promoted former CFO Brittany Bradrick to COO and CFO. Ms. Bradrick’s impact both within Neurelis and among our
- [NEURELIS ANNOUNCES PRESENTATION OF ANALYSIS OF TIME BETWEEN SEIZURE CLUSTERS WITH VALTOCO® (DIAZEPAM NASAL SPRAY) CIV AT THE 2022 ANNUAL MEETING OF THE ACADEMY OF MANAGED CARE PHARMACY](https://www.neurelis.com/neurelis-announces-presentation-analysis-time-between-seizure-clusters-valtocor-diazepam-nasal/) - Analysis of 12-month, Phase 3 study shows 2-fold increase in time between VALTOCO treated seizure clusters, or SEIzure interVAL (SEIVAL) SAN DIEGO, CA — October 12, 2022 — Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet
- [Neurelis will Highlight Analyses of Seizure Treatment with Diazepam Nasal Spray at the American Academy of Neurology Annual Meeting](https://www.neurelis.com/neurelis-will-highlight-analyses-of-seizure-treatment-with-diazepam-nasal-spray-at-the-american-academy-of-neurology-annual-meeting/) - Presentations include post hoc analyses assessing at home treatment of status epilepticus, acute seizure termination and rapid and early seizure termination, and treatment of prolonged seizures. San Diego, CA – April 7, 2025 – Neurelis, Inc., today announced details of three poster presentations at the American Academy of Neurology (AAN) Annual Meeting to be held
- [Neurelis Presents Studies on Seizure Clusters at the American Epilepsy Society Annual Meeting](https://www.neurelis.com/neurelis-presents-studies-on-seizure-clusters-at-the-american-epilepsy-society-annual-meeting/) - Ten poster presentations highlight analyses of immediate-use seizure medication and treatment for seizure clusters
- [Neurelis to Join Epilepsy Community at 12th Annual Sofie's Journey Epilepsy Awareness Day and Education Expo at Disneyland® Resort](https://www.neurelis.com/neurelis-join-epilepsy-community-12th-annual-sofies-journey-epilepsy-awareness-day-and-education/) - One of the largest gatherings of people with epilepsy, care partners, and healthcare practitioners to address unmet needs for increased education
- [Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties](https://www.neurelis.com/eurelis-enters-208-million-agreement-monetize-intravail-royalties/) - OrbiMed agrees to purchase Neurelis’ rights and interests in ARS Pharmaceuticals’ neffy® global net sales royalties and milestones
- [NEURELIS PRESENTS NOVEL, INVESTIGATIONAL ANALYSIS OF VALTOCO® (DIAZEPAM NASAL SPRAY) CIV DEMONSTRATING INCREASED TIME BETWEEN SEIZURE CLUSTERS AT THE 51ST CHILD NEUROLOGY SOCIETY ANNUAL MEETING](https://www.neurelis.com/neurelis-presents-novel-investigational-analysis-valtocor-diazepam-nasal-spray-civ-demonstrating/) - Two posters highlight findings from a long term safety study of VALTOCO in a pediatric population The first features investigational data indicating a doubling of time between VALTOCO treated seizure clusters across 12 months The second summarizes a sub-analysis showing no long-term safety differences for VALTOCO in patients with Lennox-Gastaut Syndrome and other pediatric epileptic
- [NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE 76TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY](https://www.neurelis.com/neurelis-announces-two-poster-presentations-76th-annual-meeting-american-academy-neurology/) - Findings include analysis of seizure cluster treatment patterns with use of VALTOCO® (diazepam nasal spray) CIV and characterization of a diazepam dosing regimen in an animal model
- [Neurelis Pipeline Update - Advancements to Address Unmet Needs in Neuroscience – Replay](https://www.neurelis.com/neurelis-pipeline-update-advancements-address-unmet-needs-neuroscience-replay/) - Neurelis hosted an investor call to highlight updates on two of its neuroscience product development candidates, NRL-1004 for acute agitation episodes and NRL-1049 for cerebral cavernous malformations (CCMs). A replay can be found at the link here.
- [NEURELIS ANNOUNCES NEW ROLES FOR TOP EXECUTIVES TO ADVANCE CLINICAL AND STRATEGIC INITIATIVES AND POSITION FOR FUTURE GROWTH](https://www.neurelis.com/neurelis-announces-new-roles-top-executives-advance-clinical-and-strategic-initiatives-and-position/) - Dr. Rabinowicz and Dr. Carrazana have been instrumental in synergistically advancing novel therapies to address unmet needs in the epilepsy and broader central nervous system (CNS) communities SAN DIEGO, CA — May 15, 2023 — Neurelis, Inc., announced today the promotion of Adrian L. Rabinowicz, MD, to Chief Medical Officer and the establishment of a
- [NEURELIS ANNOUNCES FOUR POSTER PRESENTATIONS AT THE 75TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY](https://www.neurelis.com/neurelis-announces-four-poster-presentations-75th-annual-meeting-american-academy-neurology/) - Quality of life and overall duration of seizures data with use of VALTOCO® (diazepam nasal spray) CIV to be presented at AAN SAN DIEGO, CA — April 25, 2023 — Neurelis, Inc. will present four posters from the completed long-term, open-label, repeat-dose safety study of VALTOCO for the treatment of episodes of frequent seizure activity
- [NEURELIS ANNOUNCES FIRST HEALTHY SUBJECTS DOSED IN INVESTIGATIONAL STUDY OF NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS](https://www.neurelis.com/neurelis-announces-first-healthy-subjects-dosed-investigational-study-nrl-1049-rho-kinase-rock/) - First in human study will evaluate safety, tolerability, and pharmacokinetic parameters of NRL-1049, a Rho kinase (ROCK) inhibitor SAN DIEGO, CA — March 24, 2023 — Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment for people living with cerebral cavernous
- [NEURELIS WINS 2023 PM360 PHARMA CHOICE MULTICHANNEL GOLD AWARD FOR ‘GIVE SEIZURES THE SPRAYER’ MARKETING CAMPAIGN](https://www.neurelis.com/neurelis-wins-2023-pm360-pharma-choice-multichannel-gold-award-give-seizures-sprayer-marketing/) - 'Give Seizures the Sprayer’, marketing campaign led by Beth Henriksen, Director of Marketing, Neurelis, Inc., wins the 2023 PM360 Pharma Choice Multichannel Gold Award SAN DIEGO, CA — March 2, 2023 — Neurelis, Inc. is proud to announce the ‘Give Seizures the Sprayer’ marketing campaign for VALTOCO® (diazepam nasal spray) CIV has won a 2023
- [NEURELIS ANNOUNCES FILING OF ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR NRL-1049, A RHO KINASE (ROCK) INHIBITOR WITH POTENTIAL TO TREAT CEREBRAL CAVERNOUS MALFORMATIONS](https://www.neurelis.com/neurelis-announces-filing-its-investigational-new-drug-application-nrl-1049-rho-kinase-rock/) - Pre-clinical data recently presented at Society for Neuroscience’s annual meeting demonstrates NRL-1049 potential safety, Neurelis to advance further studies SAN DIEGO, CA — January 9, 2023 — Neurelis, Inc., announced the successful filing of its investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NRL-1049, a Rho kinase (ROCK) inhibitor with
- [NEURELIS CONGRATULATES INTRAVAIL® LICENSEE, ARS PHARMACEUTICALS, FOR FDA ACCEPTANCE OF INTRANASAL EPINEPHRINE NDA](https://www.neurelis.com/neurelis-congratulates-intravailr-licensee-ars-pharmaceuticals-fda-acceptance-intranasal/) - neffy® (epinephrine nasal spray), is developed with Neurelis’ proprietary Intravail® Absorption-Enhancing Technology SAN DIEGO, CA — December 8, 2022 — ARS Pharmaceuticals, Inc., announced that the U.S. Food & Drug Administration (FDA) has accepted its New Drug Application (NDA) for neffy (previously referred to as ARS-1), for the emergency treatment of severe type I allergic
- [NEURELIS TO PRESENT NINE POSTERS AT THE 76th AMERICAN EPILEPSY SOCIETY ANNUAL MEETING](https://www.neurelis.com/neurelis-present-nine-posters-76th-american-epilepsy-society-annual-meeting/) - Investigational Phase 3 study of VALTOCO® (diazepam nasal spray) CIV shows double the time between seizure clusters when administered over a 12-month period Poster addresses myths associated with rescue therapy for seizure clusters Additional poster highlights investigational non-surgical treatment option for cerebral cavernous malformations SAN DIEGO, CA — December 2, 2022 — Neurelis, Inc., announced
- [Neurelis, Inc. to Participate in the 5th Annual Evercore ISI HealthCONx Conference](https://www.neurelis.com/neurelis-inc-participate-5th-annual-evercore-isi-healthconx-conference/) - SAN DIEGO, CA — November 28, 2022 — Neurelis, Inc., a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need, today announced that corporate leadership will participate in a fireside chat and one-on-one investor meetings at the 5th
- [NEURELIS SUPPORTS SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT](https://www.neurelis.com/neurelis-supports-sofies-journey-epilepsy-awareness-day-and-education-expo-disneylandr-resort/) - Largest, worldwide epilepsy community gathering will feature a physician presentation on VALTOCO® (diazepam nasal spray) CIV for frequent seizure activity Little Angels Service Dogs’ seizure alert and response puppies-in-training to appear at Neurelis booth and for onstage demonstrations SAN DIEGO, CA — October 31, 2022 — Neurelis is a proud supporter of the 10th Annual
- [NEURELIS RANKED THIRD BEST PLACE TO WORK IN SoCAL 2022](https://www.neurelis.com/neurelis-ranked-third-best-place-work-socal-2022/) - SAN DIEGO, CA — October 24, 2022 — Neurelis, Inc., is pleased to announce it was ranked third among medium-size employers on the Best Places to Work in SoCal 2022 list by Best Companies Group (BCG), a BridgeTower Media Company. This distinction is based on responses from a detailed and comprehensive survey of its employees.

## Pages

- [Home](https://www.neurelis.com/) - Learn about Neurelis®, a neuroscience-based pharmaceutical company developing life-changing treatments that empower patients and HCPs to define their own journey.
- [Board of Directors](https://www.neurelis.com/about-neurelis/board-of-directors/) - Discover the Neurelis Board of Directors, which possesses all the relevant experience needed to help a specialty pharmaceutical company thrive.
- [Leadership](https://www.neurelis.com/about-neurelis/leadership/) - Meet the passionate individuals behind the pharmaceutical company Neurelis, including President and CEO/Co-Founder Craig C. Chambliss.
- [California Declaration](https://www.neurelis.com/california-declaration/) - Neurelis Annual Declaration of Compliance based on a good faith understanding of the requirements of Section 119402 of the California Health & Safety Code.
- [Careers](https://www.neurelis.com/careers/) - Neurelis is changing the way silent chronic/acute central nervous system (CNS) disorders are treated. See current opportunities to join the Neurelis family.
- [Our Pipeline](https://www.neurelis.com/our-pipeline/) - Review the pipeline of products Neurelis® has developed that enables patients with epilepsy or CNS disorders to gain greater control of their treatment journeys.
- [Our Product](https://www.neurelis.com/our-product/) - Learn more about VALTOCO® (diazepam nasal spray) CIV. See full Prescribing Information, including Boxed Warning, and instructions for use.
- [Contact Us](https://www.neurelis.com/contact-us/) - Contact the pharmaceutical company Neurelis with any questions about the company or about any Neurelis products currently in development.
- [Privacy Policy](https://www.neurelis.com/privacy-policy/) - Home – Privacy Policy NEURELIS PRIVACY NOTICE Last updated on August 31, 2024Neurelis, Inc. (“Neurelis”, “we”, “us”, “our”) respects your privacy and is committed to protecting your Personal Information. This Privacy Notice describes the types of Personal Information we collect and our practices for using, maintaining, sharing, and protecting it. It also describes the rights
- [Washington's Consumer Health Privacy Policy](https://www.neurelis.com/washingtons-consumer-health-privacy-policy/) - Home – Washington’s Consumer Health Privacy Policy NEURELIS CONSUMER HEALTH DATA PRIVACY POLICY This Consumer Health Data Privacy Policy (“Health Data Policy”) describes how Neurelis, Inc. (“Neurelis”, “we,” “us” or “our”) processes “Consumer Health Data,” as that term is defined under applicable state privacy law, about consumers who reside in the states of Nevada, Washington,
- [Terms of Use](https://www.neurelis.com/terms-of-use/) - Home – Terms of Use Terms and ConditionsBy accessing or using this website, you acknowledge that you have read, understood and agreed to the Terms & Conditions. If you do not agree to the Terms & Conditions, do not access or use the website.Neurelis, Inc. (“Neurelis” or the “Company”) may modify this website and the
- [myNEURELIS](https://www.neurelis.com/myneurelis/) - Discover myNeurelis® for patient, care partner, and HCP support. Access nurse education programs, epilepsy resources, copay information, and more.
- [Sign Up for Neurelis Company News](https://www.neurelis.com/neurelis-news/signup/) - Sign up to receive the latest news from Neurelis and stay up-to-date on all news, events, and pipeline information about the pharmaceutical company.
- [Neurelis News](https://www.neurelis.com/neurelis-news/) - Stay current with the latest Neurelis® news, including financing information, drug development, and more, as it pertains to pharmaceuticals and biotech.
- [Our Partners](https://www.neurelis.com/our-partners/) - Neurelis® is proud to work with pioneering companies that share the company vision of advancing medical science. Meet the partners.
- [Our Science and Technologies](https://www.neurelis.com/our-science-and-technologies/) - See the portfolio of Neurelis® technologies that accelerate product development and drug performance to provide progressive solutions for unmet medical needs.
- [NRL-1004](https://www.neurelis.com/our-pipeline/nrl-1004/) - We are developing NRL-1004, a proprietary nasal spray formulation, for the treatment of acute agitation in people with schizophrenia and bipolar disorder.
- [NRL-1049](https://www.neurelis.com/our-pipeline/nrl-1049/) - Review NRL-1049, an investigational Phase 1 stage small molecule, Rho kinase (ROCK) inhibitor with the potential to address people suffering from CCMs.
- [About Neurelis](https://www.neurelis.com/about-neurelis/) - Neurelis® is a neuroscience-based specialty pharmaceutical company providing innovative approaches to target unmet medical needs. Learn about the company here.
- [Community Involvement](https://www.neurelis.com/about-neurelis/community-involvement/) - Discover how Neurelis® is accelerating the development of therapeutic options through meaningful partnerships with advocacy associations and professional societies.

## Categories

- [News](https://www.neurelis.com/category/news/)